NIH funding announcement: Microphysiological Systems for Disease Modeling and Efficacy Testing

Home / Community Blog / NIH funding announcement: Microphysiological Systems for Disease Modeling and Efficacy Testing

Community Blog

NIH funding announcement: Microphysiological Systems for Disease Modeling and Efficacy Testing

Source: http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-16-017.html

Title: Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing (UG3/UH3) 

Funding Opportunity Announcement: RFA-TR-16-017

Purpose

The purpose of the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program is to develop highly reproducible and translatable in vitro models for preclinical efficacy studies through discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy testing and definitive efficacy testing of candidate therapeutics using best practices and rigorous study design. An essential feature will be a multidisciplinary approach that brings together experts in bioengineering, microfluidics, material science, “omic” sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science.

Funds from the NIH will be made available through the UG3/UH3 cooperative agreement award mechanism. The initial UG3 phase will support studies to develop in vitro disease models using tissue chip technologies and iPSC and/or primary tissues derived from patients, and functional validation of the models.   The UH3 phase will support studies to demonstrate the functional utility of the disease models for identification of novel treatment mechanisms through better understanding of disease biology, drug screening, assessment of candidate therapies for efficacy and safety assessments, and establishing the pre-clinical foundation that will inform clinical trial design. A UG3 project that meets its milestones will be administratively considered by NCATS and other participating ICs and prioritized for transition to the UH3 award. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases.

Key Dates

Open Date (Earliest Submission Date): October 29, 2016

Letter of Intent Due Date(s): New Date as per issuance of NOT-TR-17-005 – November 13, 2016

Application Due Date(s): New Date as per issuance of NOT-TR-17-005 – December 13, 2016 by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Leave a Comment

*